The treatment has the potential to “extend lifespans and improve quality of life” in patients with brain cancer, according to experts at UC San Diego Health. 

Adoption of PSMA-PET has been swift because it can significantly improve prostate cancer detection and treatment. SNMMI President Munir Ghesani, MD, explains how.

In a close collaboration with radiation oncologists, experts trained their model on the CT lung images of 787 patients and tested it on the scans of more than 1,300 patients from external datasets.

The authors stated that their results should not deter providers from offering their patients radiotherapy treatment but rather encourage in-depth discussions and shared decisions pertaining to the best options.

PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam. 

The model performed well in assessing treatment responses, but experts explained that one of the most beneficial aspects of their model was that its results are interpretable in a “clinician-friendly way.” 

The study touts the benefits of targeted radionuclide alpha therapy for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have not had success with other treatments.

Men with prostate cancer can avoid many of the unpleasant side effects of chemo, surgery and radiation therapy when they are treated with high-intensity focused ultrasound instead.